Business Wire

ZS Launches ZAIDYN™ Clinical Development, Expanding Its Digital Life Sciences Platform

17.6.2022 16:45:00 EEST | Business Wire | Press release

Share

Global management consulting and technology firm ZS has announced the launch of ZAIDYN Clinical Development. The offering is the latest expansion of the platform ZAIDYN by ZS, designed to empower life sciences companies to digitally transform and scale customer engagement, field performance, analytics and—now—clinical development design and planning.

“Today, we’re announcing the launch of ZAIDYN Clinical Development, expanding on more than 35 years of software expertise,” said Sanjay Joshi, managing principal and platform lead for ZS. “With ZAIDYN, life sciences organizations can connect their global teams, products, processes, applications, algorithms and data assets for powerful insights to shape clinical research and accelerate clinical development timelines. Our platform works with existing IT systems to fuel efficiency and connectivity, reduce costs and empower life sciences companies of all sizes to innovate, scale and grow as the global healthcare ecosystem evolves.”

ZAIDYN Clinical Development harnesses the power of a self-learning network, AI-driven insights and algorithms to create a fluid, fast, frictionless trial experience for business users, site investigators and patients. With our products, companies have the power to:

  • Drive innovation and decision-making throughout the clinical development process with insightful, dynamic reporting and analytics for clinical teams and a high-level view of clinical trial operations for leaders
  • Optimize clinical study planning and protocol design using AI and predictive insights that reflect the experiences and perspectives of participants and patients
  • Empower teams to test and model site and enrollment scenarios to find ways to make studies more inclusive and engaging, lift participant burden, limit amendments and accelerate trial efficiency
  • Create an expanding universe of industry and historical clinical trial data, real-world data, site criteria and patient survey insights
  • Raise the bar for clinical research with products built on Amazon Web Services (AWS) that apply the latest clinical data standards and fuel connectivity throughout upstream and downstream systems

More than 130 companies already use ZS’s products to drive business decisions. Now, these companies can combine the clinical expertise of ZS consulting with the latest features of ZAIDYN Clinical Development to break down business and clinical silos and empower teams to work together more efficiently.

“ZAIDYN Clinical Development will help our clients navigate the large-scale, disruptive changes we see happening across our industry—and those on the horizon as AI and machine learning transform clinical research and development (R&D),” said Aaron Mitchell, ZS’s global R&D excellence practice leader. “Smarter platforms for life sciences can help us improve clinical trial diversity, bring life-saving therapies to patients faster, and unlock patterns and breakthroughs that will transform the future of clinical research. It’s all about using insights from data more effectively to drive more inclusive studies and better patient outcomes.”

“With the support of ZS and the ZAIDYN platform, we’re accelerating the transformation we initiated three years ago,” reflected Cynthia Deparis, program manager at Sanofi. “The platform is helping us take a data-driven approach to identifying the best countries and sites for clinical studies. It’s helped us integrate and expand the universe of clinical operational trial data so we can target sites and countries that help us deliver on our development portfolio and think through various strategic parameters like the competitive landscape, our peers’ activity, historical knowledge about sites and feedback from outreached sites. With these insights and the ability to model different scenarios, we can continue to optimize recruitment and enhance the accuracy of our projections, setting our clinical trial development on a continuous improvement cycle.”

About ZS

ZS is a management consulting and technology firm focused on transforming global healthcare and beyond. We leverage our leading-edge analytics, plus the power of data, science and products to help our clients make more intelligent decisions, deliver innovative solutions and improve outcomes for all. Founded in 1983, ZS has more than 12,000 employees in 35 offices worldwide. To learn more, visit www.zs.com or follow us on Twitter and LinkedIn.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Quintin Maidment; ZS@theblissgrp.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Chiesi Group Announces New Chair and Vice Chair20.5.2026 12:00:00 EEST | Press release

Chiesi today announced a planned leadership change in its Board of Directors: Maria Paola Chiesi has been appointed Chair of the Board, succeeding Alessandro Chiesi, who is completing his tenure after nearly three years in the role, and will now continue to serve as Vice Chair. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260520447292/en/ Maria Paola Chiesi is appointed Chair of Chiesi Board of Directors, the first woman in this role; aims to reinforce sustainability as an integral and enduring pillar of the Group’s strategy During his mandate, Alessandro Chiesi oversaw the Group through a phase of continued international development and governance strengthening, thereby further consolidating Chiesi’s long-term strategy as a research focused biopharmaceutical company and certified B Corp. “It has been my privilege to serve as Chair during a period of evolution for Chiesi,” said Alessandro Chiesi. “What has remained unchang

Insurance Investment Outsourcing Surpasses $5.5 Trillion as Private Markets and Global Expansion Reshape the Industry20.5.2026 10:00:00 EEST | Press release

Clearwater Analytics (NYSE: CWAN) today released the 2026 Insurance Investment Outsourcing Report (IIOR), produced in partnership with DCS Financial Consulting. The report captures $5.5 trillion in third-party general account insurance assets under management across 96 asset managers, a 23% increase year-over-year and a 65% increase since 2021, alongside $1.8 trillion in assets under advisement across 12 investment consultants. The findings point to an outsourcing market that has become larger, more global, and materially more complex. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260520780028/en/ The 2026 IIOR reveals defining trends reshaping insurance investment management: Private Markets Cross a Threshold. Third-party private insurance AUM has more than doubled since 2021, reaching $947 billion and approaching one-third of outsourced insurance allocations alongside public assets. Insurers have moved steadily beyond tra

Factbird Adds Quality & Compliance and Reports to its Manufacturing Intelligence Platform20.5.2026 09:00:00 EEST | Press release

Today, Factbird is announcing two major additions to its manufacturing intelligence platform: Quality & Compliance and Factbird Reports. Both address a problem that compounds as manufacturers grow. More sites mean more variation in how work gets done. More regulation means more documentation pressure on frontline teams. And more data, when fragmented across systems, often slows decisions rather than speeding them up. Solving this has traditionally meant large IT projects and months of deployment. “Enterprise manufacturers shouldn’t have to choose between capability and simplicity,” said Mogens Arne Hansen, Chief Technology and Product Officerat Factbird. “With Quality & Compliance and Reports, you can have standardized, audit-ready operations and automated performance reporting across every site, deployed in days, used by the people on the floor.” Quality & Compliance: standardized, compliant operations across every site Regulated manufacturers in food and beverage, pharma, and medical

The LYCRA Company to Successfully Complete Comprehensive Financial Restructuring20.5.2026 05:23:00 EEST | Press release

The LYCRA Company, LLC (“the Company”), a global leader in developing fiber and technology solutions for the apparel and personal care industries, will successfully complete its comprehensive financial restructuring process and emerge from Chapter 11 protection on May 20, 2026. The LYCRA Company has established a durable capital structure that will enable the Company’s pursuit of its growth strategy through investment in innovation, customer partnerships, and global operations. The Company will emerge from its comprehensive restructuring process with significantly enhanced financial flexibility and a strengthened balance sheet to support long-term growth. The Company will have reduced its total long-term debt by more than $1.2 billion and will obtain more than $75 million in new money investment. Throughout the process, the Company has maintained uninterrupted operations and continues to deliver on commitments to its employees, customers, and vendors. The LYCRA Company will be supporte

Johns Manville Announces John Vasuta as New CEO19.5.2026 23:30:00 EEST | Press release

Johns Manville (JM), a global building and specialty products manufacturer and a Berkshire Hathaway company, announced today that Bob Wamboldt will retire and John Vasuta will assume the role of President and Chief Executive Officer, effective August 1, 2026. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260519630814/en/ John Vasuta will become JM's CEO and President on August 1, 2026. Vasuta joined Johns Manville in 2019 as President of the company’s Engineered Products business. He also serves on the Board of Directors for EJ, a global leader and private manufacturer of infrastructure access products for water, sewer, utilities, drainage and telecommunications. “It’s an extraordinary privilege to step into the role of CEO,” Vasuta said. “I’m deeply honored to continue serving our customers and supporting the employees whose dedication makes our success possible.” Before joining JM, John held leadership roles at Bridgeston

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye